

ACELRX PHARMACEUTICALS INC  
Form 8-K  
February 13, 2015  
UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 12, 2015**

**ACELRX PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**                      **001-35068**                      **41-2193603**  
(State of incorporation) (Commission File No.) (IRS Employer Identification No.)

**351 Galveston Drive**

**Redwood City, CA 94063**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 216-3500**

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.*****2015 Base Salaries***

On February 12, 2015, the Board of Directors (the “Board”) of AcclRx Pharmaceuticals, Inc. (the “Company”) approved the 2015 base salaries (effective retroactively to January 1, 2015) for certain of the Company’s named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission, the “NEOs”) in the amounts set forth in the table below.

<b>Named Executive Officer</b>	<b>2015 Base Salary</b>
Richard A. King, Chief Executive Officer	\$ 490,000
Timothy E. Morris, Chief Financial Officer	\$ 386,500
Pamela P. Palmer, M.D., Ph.D., Chief Medical Officer	\$ 438,000
Badri Dasu, Chief Engineering Officer	\$ 321,000
Lawrence G. Hamel, Chief Development Officer	\$ 321,000

***Bonus Payments***

On February 12, 2015, the Board approved bonus payments for 2014 performance for certain of the NEOs in the amount set forth in the table below, in accordance with the Company’s established 2014 Cash Bonus Plan.

<b>Named Executive Officer</b>	<b>2014 Bonus</b>
Richard A. King, Chief Executive Officer	\$ 91,875

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form 8-K

Timothy E. Morris, Chief Financial Officer	\$ 70,137
Pamela P. Palmer, M.D., Ph.D., Chief Medical Officer	\$ 104,987
Badri Dasu, Chief Engineering Officer	\$ 67,867
Lawrence G. Hamel, Chief Development Officer	\$ 65,695

---

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACELRX  
PHARMACEUTICALS,

Date: February 13, 2015 INC.

By:                    /s/  
                          Timothy  
                          E. Morris  
                          Timothy  
                          E. Morris  
                          Chief  
                          Financial  
                          Officer